Weight Loss Drug Semaglutide Fails to Leisurely Alzheimer’s Progression

Despite initial optimism stemming from observational studies and biomarker changes, recent Phase 3 clinical trials published in The Lancet have demonstrated that oral semaglutide does not significantly slow the clinical progression of early Alzheimer’s disease over a two-year period.

Key Takeaways

• Oral semaglutide did not slow cognitive or functional decline in individuals with early Alzheimer’s disease.
• Two independent Phase 3 trials, evoke and evoke+, yielded the same negative clinical result.
• Semaglutide induced some biomarker alterations, but these did not translate into measurable patient benefits.
• The safety profile of semaglutide was consistent with known effects, with gastrointestinal and weight-related side effects being the most commonly reported.

Understanding Alzheimer’s Disease and the Rationale for Semaglutide

Alzheimer’s disease is a progressive neurodegenerative disorder characterized by gradual cognitive and functional decline. Interventions targeting the early stages of Alzheimer’s disease are considered crucial for delaying disease progression and minimizing long-term disability.

Semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1RA), is already approved for the treatment of type 2 diabetes, obesity, and cardiovascular risk reduction. Its potential neuroprotective effects have been investigated due to its observed impact on metabolic, vascular, and inflammatory pathways in preclinical studies. Observational research had previously suggested a possible reduced risk of dementia among patients treated with GLP-1RAs.

The Evoke and Evoke+ Trials: Design and Participants

The study analyzed data from the evoke and evoke+ trials, two large, multicenter, randomized, placebo-controlled Phase 3 trials conducted across 566 sites in 40 countries. Participants aged 55–85 years with mild Alzheimer’s dementia or mild cognitive impairment (MCI) and confirmed amyloid pathology were included. Patients received flexible doses of oral semaglutide (up to 14 mg) or a placebo for 156 weeks, in addition to standard care. The primary endpoint was the change in cognitive and functional decline, measured by the Clinical Dementia Rating Sum of Boxes (CDR-SB) at week 104.

Trial Results: No Significant Cognitive Benefit

The results of both trials indicated that semaglutide did not demonstrate a statistically significant improvement in cognitive or functional outcomes compared to the placebo. The difference in CDR-SB scores between the treatment and placebo groups was minimal. No significant effects were observed across secondary endpoints, including measures of memory, cognitive assessments, and daily functioning. Due to the fact that the primary endpoint was not met, further statistical testing was not performed.

Safety and Biomarker Analysis

Semaglutide’s safety profile was consistent with previous studies. Common adverse effects included weight loss, reduced appetite, and gastrointestinal symptoms such as nausea. While adverse events were slightly more frequent in the semaglutide group, serious safety outcomes, including fatalities, were similar between the two groups. Biomarker analyses revealed reductions in inflammatory markers, such as high-sensitivity C-reactive protein, and modest improvements in cerebrospinal fluid markers associated with neuroinflammation and neurodegeneration. However, these biological changes did not translate into measurable clinical benefits.

Implications for Alzheimer’s Treatment

These findings suggest that oral semaglutide does not slow cognitive or functional decline in patients with early-stage Alzheimer’s disease over a two-year period. Despite promising signals from observational and preclinical research, this large-scale clinical trial does not support the use of semaglutide as a disease-modifying therapy for this population. Variations between this trial and earlier studies may be attributed to differences in patient populations, treatment duration, or study design, including the distinction between preventing and treating symptomatic disease.

Future Research Directions

Although semaglutide demonstrated some favorable biomarker changes, further research is warranted to determine whether GLP-1RAs may have a role in earlier or preventive stages of Alzheimer’s disease. Future studies may also explore combination therapies, longer treatment durations, or different patient subgroups to better understand potential therapeutic benefits. These results highlight the complexity of translating metabolic and anti-inflammatory effects into meaningful clinical outcomes in neurodegenerative diseases.